Total Payments
$1.4M
2024 Payments
$67,160
Companies
39
Transactions
1,558
Medicare Patients
1,040
Medicare Billing
$210,852
Payment Breakdown by Category
Other$1.1M (75.3%)
Travel$228,651 (16.2%)
Consulting$88,861 (6.3%)
Food & Beverage$32,037 (2.3%)
Education$493.58 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 369 | 72.7% |
| Travel and Lodging | $228,651 | 627 | 16.2% |
| Consulting Fee | $88,861 | 41 | 6.3% |
| Honoraria | $35,237 | 18 | 2.5% |
| Food and Beverage | $32,037 | 495 | 2.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.0% |
| Education | $493.58 | 7 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $283,248 | 270 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $212,769 | 273 | $0 (2023) |
| Amgen Inc. | $124,423 | 162 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $107,581 | 157 | $0 (2022) |
| Celgene Corporation | $100,405 | 106 | $0 (2022) |
| Gilead Sciences, Inc. | $77,902 | 72 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $71,394 | 66 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $65,537 | 38 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $61,416 | 51 | $0 (2021) |
| Incyte Corporation | $56,765 | 74 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67,160 | 83 | Janssen Biotech, Inc. ($34,517) |
| 2023 | $91,207 | 89 | Janssen Biotech, Inc. ($21,953) |
| 2022 | $147,610 | 116 | Janssen Biotech, Inc. ($49,434) |
| 2021 | $86,601 | 79 | Janssen Biotech, Inc. ($32,072) |
| 2020 | $76,737 | 66 | Janssen Biotech, Inc. ($29,772) |
| 2019 | $291,234 | 347 | Janssen Biotech, Inc. ($60,430) |
| 2018 | $319,655 | 401 | Bayer HealthCare Pharmaceuticals Inc. ($91,656) |
| 2017 | $335,563 | 377 | Pharmacyclics LLC, An AbbVie Company ($50,979) |
All Payment Transactions
1,558 individual payment records from CMS Open Payments — Page 1 of 63
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: Oncology | ||||||
| 12/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $45.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $83.77 | General |
| Category: Oncology | ||||||
| 12/03/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Oncology | ||||||
| 11/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $147.13 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,744.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/17/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,148.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/08/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $3,328.59 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 09/07/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $81.51 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 09/03/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 08/27/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: HEMATOLOGY | ||||||
| 08/13/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Travel and Lodging | Cash or cash equivalent | $15.93 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Travel and Lodging | Cash or cash equivalent | $12.25 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Travel and Lodging | Cash or cash equivalent | $4.00 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 07/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 06/28/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $2,048.42 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Travel and Lodging | In-kind items and services | $220.99 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $89.96 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 06/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 385 | 947 | $326,398 | $74,863 |
| 2022 | 7 | 285 | 818 | $287,482 | $65,761 |
| 2021 | 5 | 204 | 527 | $168,025 | $38,561 |
| 2020 | 5 | 166 | 428 | $131,627 | $31,666 |
Total Patients
1,040
Total Services
2,720
Medicare Billing
$210,852
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 264 | $72,072 | $19,439 | 27.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 102 | 290 | $80,330 | $16,242 | 20.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 94 | $37,036 | $10,339 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 69 | 123 | $49,996 | $10,261 | 20.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 52 | $40,092 | $7,977 | 19.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 35 | 35 | $18,270 | $4,284 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 17 | $8,753 | $2,210 | 25.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 34 | $4,998 | $1,604 | 32.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 11 | 11 | $6,985 | $1,282 | 18.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 13 | 13 | $5,486 | $790.10 | 14.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 11 | 14 | $2,380 | $434.46 | 18.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 100 | 323 | $89,471 | $18,305 | 20.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 28 | 171 | $67,374 | $16,491 | 24.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 175 | $47,775 | $11,810 | 24.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 46 | 56 | $43,176 | $10,414 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 39 | 53 | $21,783 | $4,807 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 19 | 19 | $12,065 | $2,499 | 20.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 13 | 21 | $5,838 | $1,435 | 24.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 91 | 273 | $75,621 | $17,041 | 22.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 159 | $43,407 | $10,897 | 25.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 26 | $20,046 | $5,002 | 25.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 28 | $11,508 | $2,488 | 21.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 17 | 17 | $10,795 | $2,129 | 19.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 24 | $6,648 | $1,005 | 15.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 78 | 221 | $61,217 | $14,425 | 23.6% |
About Dr. Perry Cook, M.D
Dr. Perry Cook, M.D is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1336140581.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Perry Cook, M.D has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $67,160 received in 2024. These payments were reported across 1,558 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Cook has provided services to 1,040 Medicare beneficiaries, totaling 2,720 services with total Medicare billing of $210,852. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 08/09/2005
- Last Updated 10/10/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336140581
Products in Payments
- DARZALEX (Biological) $199,213
- IMBRUVICA (Drug) $176,420
- Imbruvica (Drug) $174,684
- Nplate (Biological) $122,714
- NINLARO (Drug) $111,158
- Aliqopa (Drug) $107,548
- Revlimid (Drug) $77,385
- Zydelig (Drug) $65,627
- JAKAFI (Drug) $56,666
- BRUKINSA (Drug) $51,441
- Tavalisse (Drug) $38,612
- Rezlidhia (Drug) $26,924
- Copiktra (Drug) $19,449
- SARCLISA (Biological) $17,382
- Pomalyst (Drug) $16,643
- TASIGNA (Drug) $15,986
- TAZVERIK (Drug) $12,874
- TECVAYLI (Biological) $11,172
- Tazverik (Drug) $9,918
- ONUREG (Drug) $8,362
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Yiwu Huang, Md, MD
Hematology & Oncology — Payments: $268,275
Hematology & Oncology $268,275
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Hematology & Oncology $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Hematology & Oncology $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Hematology & Oncology $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699
Hematology & Oncology $48,699
Yan Pronin, P.a, P.A
Hematology & Oncology — Payments: $47,040
Hematology & Oncology $47,040